Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

BMC Health Services Research

Volumn 15, Issue 1, 2015, Pages

  Charokopou, M ^a   McEwan, P ^b,c   Lister, S ^d   Callan, L ^e   Bergenheim, K ^f   Tolley, K ^g   Postema, R ^d   Townsend, R ^e   Roudaut, M ^d  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g Tolley Health Economics Ltd   (United Kingdom)

Author keywords

Cost effectiveness analysis; DPP 4i; SGLT 2; Type 2 diabetes mellitus

Indexed keywords

2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSIDE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER;

ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMIC MODEL; ECONOMICS; HUMAN; NATIONAL HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UNITED KINGDOM;

BENZHYDRYL COMPOUNDS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MODELS, ECONOMIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SODIUM-GLUCOSE TRANSPORT PROTEINS; STATE MEDICINE; UNITED KINGDOM;

EID: 84946195706     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-015-1139-y     Document Type: Article

References (46)

1. Diabetes UK. Diabetes in the UK 2012: Key statistics on diabetes. 2012. Available at: http://www.diabetes.org.uk/About-us/What-we-say/Statistics/Diabetes-in-the-UK-2012/. Last accessed October 2015.
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855-62.
3. National Collaborating Centre for Chronic Conditions (UK). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). 2008. Available at http://www.nice.org.uk/guidance/CG066. Last accessed October 2015.
4. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2012;35(6):1364-79.
5. Hu FB. Globalization of Diabetes: the role of diet, lifestyle, and genes. Diabetes care. 2011;34(6):1249-57.
6. Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014;16(5):433-42.
7. Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med. 2015;32(7):890-8.
8. van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clinical drug investigation. 2014;34(2):135-46.
9. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. Available at: https://www.nice.org.uk/article/pmg9/. Last accessed October 2015.
10. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010;12(7):623-30.
11. The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications. Diabetes care. 2007;30(6):1638-46.
12. Palmer AJ, Clarke P, Gray A, Leal J, Lloyd A, Grant D, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2013;16(4):670-85.
13. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747-59.
14. Office of National Statistics. UK Life Expectancy Tables. Available at: http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Life+Tables . Last accessed October 2015.
15. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020-31.
16. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes care. 2011;34(9):2015-22.
17. Del Prato S, Nauck M, Rohwedder K, Theuerkauf A, Langkilde A, Parikh S. Long-term efficacy and safety of dapagliflozin vs add-on glipizide in patients with type 2 diabetes inadequately controlled with metformin: 2 year results. A 47th Annual Meeting of the European Association for the Study of Diabetes. 2011.
18. Del Prato S, Nauck M, Duran-Garcia S, Rohwedder K, Theuerkauf A, Langkilde A, et al. Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data. American Diabetes Association. 2013:21-5.
19. Nauck M, Del Prato S, Rohwedder K, Elze M, Parikh S. Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomized, controlled trial. Diabetologia. 2010;53(S1):S339
20. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619-31.
21. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med. 2003;20(6):442-50.
22. National Health Services (NHS) Business Services Authority. NHS Drug Tariff; 2012.
23. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22(4):340-9.
24. Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health. 2005;8(5):581-90.
25. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997;44(1):49-60.
26. Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30(7):1267-73.
27. Fox KM, Gerber Pharmd RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2006;28(3):388-95.
28. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57(539):455-60.
29. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217-30.
30. Mohamed AF, Zhang J, Johnson FR, Lomon ID, Malvolti E, Townsend R, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39(5):397-403.
31. Cummins E, Scott N, Rothnie K, Waugh N, Fraser C, Philip S et al. Dapagliflozin for the treatment of type 2 diabetes. Aberdeen HTA Group, Institute of Applied Health Sciences, University of Aberdeen. 2012.
32. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(S1):S5-26.
33. Charokopou M, Sabater FJ, Townsend R, Roudaut M, Verheggen BG. Overview of health economic models in type 2 diabetes mellitus (T2DM); a systematic literature review. Value Health. 2013;16(7):A591.
34. Yang F, Ye J, Pomerantz K, Stewart M. Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials. Diabetes, metabolic syndrome and obesity : targets and therapy. 2013;6:247-56.
35. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925-33.
36. National Institute for Health and Care Excellence. Technology appraisal 288: Dapagliflozin in combination therapy for treating type 2 diabetes. 2013. Available at: https://www.nice.org.uk/guidance/ta288. Last accessed October 2015.
37. Alva M, Gray A, Mihaylova B, Clarke P. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ. 2014;23(4):487-500.
38. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2010;375(9733):2223-33.
39. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523-34.
40. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting - a multicentre study. Nephrol Dial Transplant. 2008;23(6):1982-9.
41. Hammer M, Lammert M, Mejias SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281-90.
42. Personal Social Services Research Unit. Unit costs of health and social care. 2012. Available at: http://www.pssru.ac.uk/project-pages/unit-costs/2012/index.php. Last accessed October 2015.
43. NHS Kidney Care. Developing robust reference costs for kidney transplantation in adults. 2010.
44. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81(2):184-9
45. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14(36):1-248.
46. Fajardo Montanana C, Hernandez Herrero C, Rivas Fernandez M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med. 2008;25(8):916-23.